View ValuationBioElectronics 将来の成長Future 基準チェック /06現在、 BioElectronicsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長16.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Dec 03BioElectronics Corporation Appoints Sree Koneru to Its Board of DirectorsBioElectronics Corporation announced that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD. Dr. Koneru is Director of Program Management for a contract manufacturing organization that specializes in the design & development of wearable and implantable active electronic medical devices. In his previous role, Sree served as the VP of Product Development for BioElectronics Corporation, where he was responsible for prototype development, physiological testing/clinical evaluation, and regulatory submissions, culminating in several approvals from the US FDA and a CE marking. He also managed the product life cycle from conception to retail launch for domestic and international channel partners. Sree obtained his doctoral degree in Biomedical Engineering ('15) from the State University of New York at Binghamton, NY- USA. He has a background in bringing Neuromodulation (Electroceuticals) medical devices to market, with research expertise in investigating physiological responses (prototype development and clinical research) of pulsed radiofrequency electromagnetic fields. His vision is to be an industry leader in developing transcutaneous, percutaneous, implantable, and electromagnetic neuromodulation technologies, intended to treat chronic diseases.お知らせ • Mar 27BioElectronics Corporation Announces the Results and Publication of A Canine Arthritis StudyBioElectronics Corporation announced the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT) device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint. Two outcomes measuring the dog's quality of life were assessed: subjectively determined changes in eight behaviors associated with discomfort, and objectively determined changes in passive range of motion (PROM). BioElectronics' Model 088 device was secured near the cervical region of the dog's spine. PROM measures were taken at baseline and day 14. Behavioral measures were taken daily. Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Most changes occurred within the first 8 days of treatment. Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs. This is due to the constant wearing away of the cartilage from dogs running, jumping, and other continuous exercise. The prevalence of osteoarthritis can be as high as 20% in dogs more than a year old, with middle-aged and older dogs being at higher risk. dogs that are diagnosed with arthritis tend to be lethargic, have difficulty moving from a sitting or lying position, cracking joints, stiffness, muscle wastage, and visible pain. Current treatment options for arthritis are typically NSAIDs given alone or in combination with other disease-modifying agents. In recent years, chronic use of NSAIDs has been linked to numerous side effects, including gastrointestinal (GI) bleeding, and renal and hepatic dysfunction. Anti-inflammatory drugs such aspirin and ibuprofen may also result in side effects, such as GI bleeding. BioElectronics Model 088 applied at the cervical spine level, may have the potential to significantly improve the quality of life for dogs and other small domestic animals with OA. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.お知らせ • Feb 23Bioelectronics Corporation Announces the Publication of Pilot Study ResultsBioElectronics Corporation announced the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device. The study design had patients first wear BioElectronics' Model 088 device (about 1/2 wearing the sham device and the remaining wearing the active device) on the residual part of the limb for 28 days. After 28 days, the patient began wearing the opposite device, i.e., the sham group wearing the active device, and the treatment group wearing the active device, again for 28 days. Three major measures were obtained for both phantom pain and residual pain along with a global assessment of change in both phantom and residual pain before, during, and after each 28 days. The researchers presented their findings in a series of graphs over time depending on whether the patient was wearing the sham or active device. When wearing the sham device, patients reported, on average, no change in the median phantom limb pain or pain in the residual limb. They also reported no median change in their global assessment of pain. In contrast, when the patients were wearing the active device, they reported, on average, a 40% to 50% decrease in the median measures for both average and worst residual and phantom limb pain by day 7 and this reduction continued through day 28. Moreover, a majority of patients, when wearing the active device, reported the highest level of global change in residual pain, i.e., "very much better" by day 21 and this continued through day 28. This measure on the phantom limb pain was also positive, with the majority of subjects reporting being " much better". The researchers conclude that further study is warranted given that an identified beneficial treatment effect is associated with using BioElectronics' Model 0 88 in the setting of a low-cost and low-risk intervention. Currently, there are 1.6 million people in the United States who are living with the loss of a limb. Due to the rising number of people who have diabetes, a major cause of amputations, it is estimated that the number of amputations could grow to as many as 3.6 million by 2050. More than 7 in 10 people who have had an arm or leg amputated have pain in the lost limb, which they perceive as still present. Nearly 4 in 10 have severe pain, and many also report depression and anxiety linked with phantom limb pain making it hard to sleep, work, and take part in family and social activities. People who have phantom limb pain are often prescribed medications, including opioids, but opioid medications are effective in only about half of these patients and can also have serious side effects, including the risk of addiction. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device to address this significant unmet medical need.お知らせ • Dec 17BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail MarketBioElectronics Corporation announced that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets.お知らせ • Nov 07BioElectronics' ActiPatch Therapy To Be Marketed By DonJoy AdvantageBioElectronics Corporation announced the execution of a commercial partnership agreement with Scott Specialties Inc. to bring their innovative pain management devices to the retail consumer healthcare marketplace under the DonJoy (DJO www.djoglobal.com) Advantage product line. This commercial partnership will leverage the ActiPatch's broad indications for use and offer an active-passive treatment combination product to treat pain, increase physical functionality and improve overall quality of life. The new products will be marketed under DJO's DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap," powered by ActiPatch". このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、BioElectronics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:BIEL - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20212000N/A9/30/20212000N/A6/30/20212-100N/A3/31/20211-1-1-1N/A12/31/20201-1-1-1N/A9/30/20201-2-1-1N/A6/30/20201-2-1-1N/A3/31/20201-2-1-1N/A12/31/20191-2-1-1N/A9/30/20191-3-1-1N/A6/30/20191-3-1-1N/A3/31/20191-3-1-1N/A12/31/20181-3-1-1N/A9/30/20181-3-1-1N/A6/30/20182-2-1-1N/A3/31/20182-2-1-1N/A12/31/20172-2-1-1N/A9/30/20172-2-1-1N/A6/30/20172-2-1-1N/A3/31/20172-2-2-2N/A12/31/20162-2-1-1N/A9/30/20162-2-2-2N/A6/30/20162-2-2-2N/A3/31/20162-2-2-2N/A12/31/20152-2-2-2N/A9/30/20152-3N/A-1N/A6/30/20152-3N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BIELの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BIELの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BIELの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BIELの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BIELの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BIELの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 12:37終値2026/05/22 00:00収益2021/12/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BioElectronics Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 03BioElectronics Corporation Appoints Sree Koneru to Its Board of DirectorsBioElectronics Corporation announced that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD. Dr. Koneru is Director of Program Management for a contract manufacturing organization that specializes in the design & development of wearable and implantable active electronic medical devices. In his previous role, Sree served as the VP of Product Development for BioElectronics Corporation, where he was responsible for prototype development, physiological testing/clinical evaluation, and regulatory submissions, culminating in several approvals from the US FDA and a CE marking. He also managed the product life cycle from conception to retail launch for domestic and international channel partners. Sree obtained his doctoral degree in Biomedical Engineering ('15) from the State University of New York at Binghamton, NY- USA. He has a background in bringing Neuromodulation (Electroceuticals) medical devices to market, with research expertise in investigating physiological responses (prototype development and clinical research) of pulsed radiofrequency electromagnetic fields. His vision is to be an industry leader in developing transcutaneous, percutaneous, implantable, and electromagnetic neuromodulation technologies, intended to treat chronic diseases.
お知らせ • Mar 27BioElectronics Corporation Announces the Results and Publication of A Canine Arthritis StudyBioElectronics Corporation announced the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT) device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint. Two outcomes measuring the dog's quality of life were assessed: subjectively determined changes in eight behaviors associated with discomfort, and objectively determined changes in passive range of motion (PROM). BioElectronics' Model 088 device was secured near the cervical region of the dog's spine. PROM measures were taken at baseline and day 14. Behavioral measures were taken daily. Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Most changes occurred within the first 8 days of treatment. Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs. This is due to the constant wearing away of the cartilage from dogs running, jumping, and other continuous exercise. The prevalence of osteoarthritis can be as high as 20% in dogs more than a year old, with middle-aged and older dogs being at higher risk. dogs that are diagnosed with arthritis tend to be lethargic, have difficulty moving from a sitting or lying position, cracking joints, stiffness, muscle wastage, and visible pain. Current treatment options for arthritis are typically NSAIDs given alone or in combination with other disease-modifying agents. In recent years, chronic use of NSAIDs has been linked to numerous side effects, including gastrointestinal (GI) bleeding, and renal and hepatic dysfunction. Anti-inflammatory drugs such aspirin and ibuprofen may also result in side effects, such as GI bleeding. BioElectronics Model 088 applied at the cervical spine level, may have the potential to significantly improve the quality of life for dogs and other small domestic animals with OA. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.
お知らせ • Feb 23Bioelectronics Corporation Announces the Publication of Pilot Study ResultsBioElectronics Corporation announced the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device. The study design had patients first wear BioElectronics' Model 088 device (about 1/2 wearing the sham device and the remaining wearing the active device) on the residual part of the limb for 28 days. After 28 days, the patient began wearing the opposite device, i.e., the sham group wearing the active device, and the treatment group wearing the active device, again for 28 days. Three major measures were obtained for both phantom pain and residual pain along with a global assessment of change in both phantom and residual pain before, during, and after each 28 days. The researchers presented their findings in a series of graphs over time depending on whether the patient was wearing the sham or active device. When wearing the sham device, patients reported, on average, no change in the median phantom limb pain or pain in the residual limb. They also reported no median change in their global assessment of pain. In contrast, when the patients were wearing the active device, they reported, on average, a 40% to 50% decrease in the median measures for both average and worst residual and phantom limb pain by day 7 and this reduction continued through day 28. Moreover, a majority of patients, when wearing the active device, reported the highest level of global change in residual pain, i.e., "very much better" by day 21 and this continued through day 28. This measure on the phantom limb pain was also positive, with the majority of subjects reporting being " much better". The researchers conclude that further study is warranted given that an identified beneficial treatment effect is associated with using BioElectronics' Model 0 88 in the setting of a low-cost and low-risk intervention. Currently, there are 1.6 million people in the United States who are living with the loss of a limb. Due to the rising number of people who have diabetes, a major cause of amputations, it is estimated that the number of amputations could grow to as many as 3.6 million by 2050. More than 7 in 10 people who have had an arm or leg amputated have pain in the lost limb, which they perceive as still present. Nearly 4 in 10 have severe pain, and many also report depression and anxiety linked with phantom limb pain making it hard to sleep, work, and take part in family and social activities. People who have phantom limb pain are often prescribed medications, including opioids, but opioid medications are effective in only about half of these patients and can also have serious side effects, including the risk of addiction. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device to address this significant unmet medical need.
お知らせ • Dec 17BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail MarketBioElectronics Corporation announced that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets.
お知らせ • Nov 07BioElectronics' ActiPatch Therapy To Be Marketed By DonJoy AdvantageBioElectronics Corporation announced the execution of a commercial partnership agreement with Scott Specialties Inc. to bring their innovative pain management devices to the retail consumer healthcare marketplace under the DonJoy (DJO www.djoglobal.com) Advantage product line. This commercial partnership will leverage the ActiPatch's broad indications for use and offer an active-passive treatment combination product to treat pain, increase physical functionality and improve overall quality of life. The new products will be marketed under DJO's DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap," powered by ActiPatch".